RxDoctor Payments Data

Arvind Nirula, MD

Cardiovascular Disease · Fountain Valley, CANPI 1437285095

Payments from drug & device makers

$19,079in general payments, 2019–2025

Across 557 payments — averaging $34.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$4K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Abbott$1K
  • Novartis$1K
  • E.r. Squibb & Sons, L.L.C.$923
  • Pfizer$876
  • plus $9K from 37 others

What the payments were for

  • Travel & lodging$2,35112%
  • Food & beverage$16,70188%
  • Education$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,079 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$304,978
Medicare patients
796
Services billed
2,701

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban482$497,640
XareltoRivaroxaban130$129,989
EntrestoSacubitril/Valsartan65$64,794
FarxigaDapagliflozin Propanediol60$64,239
Repatha SureclickEvolocumab39$35,246
MultaqDronedarone Hcl29$34,702
BrilintaTicagrelor23$29,091
JardianceEmpagliflozin22$23,268
Praluent PenAlirocumab17$11,069
Rosuvastatin Calcium323$5,332
Atorvastatin Calcium319$3,722
Metoprolol Succinate260$3,708
Ranolazine ErRanolazine26$3,353
Diltiazem 24hr Er (Cd)Diltiazem Hcl69$2,254
Ezetimibe84$1,996

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$876$497,640482 claims
Johnson & JohnsonXarelto$526$129,989130 claims
AstraZenecaFarxiga, Brilinta$288$93,33083 claims
NovartisEntresto$1,064$64,79465 claims
Sanofi-aventis U.S. LLCMultaq$526$34,70229 claims
Boehringer IngelheimJardiance$490$23,26822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Fountain Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →